Manchester, UK-based Concept Life Sciences, an integrated drug discovery, development and analytical services company, has acquired Scottish contract research organisation Aquila BioMedical.
Aquila, a University of Edinburgh spin out, has expertise in preclinical contract research on therapeutics for oncology, biomarker discovery, and target expression, with services covering a wide range of in vitro and in vivo proof-of-concept studies.
According to Concept, the acquisition is “a pivotal addition” to its own services supporting the drug discovery and development process.
“The company’s offering in translational biology adds significant value to our current discovery services, and broadens the wider group’s therapy offering,” noted Concept’s executive chairman Michael Fort.
Financial terms of the deal were not disclosed.
By Selina McKee
Source: Pharma Times
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.
